Zalemark Holding Company Inc. Signed Licensing Agreement with Lupos (Canada) Biotechnology Inc.

Rhea-AI Summary

Zalemark Holding Company signed a licensing agreement with Lupos Biotechnology to develop cannabis topical products. Zalemark will market the products under their 'Aeroponleaf' trademark.

TORNONTO, ON / ACCESSWIRE / March 15, 2021 / Zalemark Holding Company Inc.(OTC PINK:ZMRK) signed Licensing Agreement with Lupos (Canada) Biotechnology Inc. to develop Cannabis topical products. This agreement will bring Zalemark in a position to market the cannabis products under their own registered "Aeroponleaf" trademark.

"We are excited to work with Lupos!" said Xia Wu, CEO of Zalemark. "Teaming up with Lupos to engage the cannabis topical products is an exciting development for our company".

"As a leading manufacturer of topicals products for the legal Canadian cannabis market, Lupos is thrilled to work with Zalemark to bring unique and innovative cannabis-based topicals to the Canadian market" said Dr. Nan Li, Founder and Chair of Lupos.

This agreement reflects Zalemark's desire to collaborate with companies that share the same visions of future of cannabis products. It also underscores Zalemark's commitment to its shareholders about cannabis products development.

Zalemark will be working closely to implement the plan. As the plan unfolds, the management team will deliver more information.

Forward Looking Statements

Information in this press release may contain ‘forward-looking statements.' Statements describing objectives or goals or the Company's future plans are also forward-looking statements and are subject to risks and uncertainties, including the financial performance of the Company and market valuations of its stock, which could cause actual results to differ materially from those anticipated. Forward-looking statements in this news release are made pursuant to the ‘Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to sales, acceptance of Zalemark Holding Company Inc.'s products, increased levels of competition, changes, dependence on intellectual property rights and other risks detailed from time to time in Zalemark Holding Company Inc. periodic reports filed with the regulatory authorities.

Email: info@zmarkholding.com

SOURCE: Zalemark Holding Company Inc.

View source version on accesswire.com:
https://www.accesswire.com/635409/Zalemark-Holding-Company-Inc-Signed-Licensing-Agreement-with-Lupos-Canada-Biotechnology-Inc

FAQ

What is the licensing agreement between Zalemark Holding Company and Lupos Biotechnology about?

The licensing agreement is for the development of cannabis topical products.

Under what trademark will Zalemark market the cannabis products?

Zalemark will market the products under their 'Aeroponleaf' trademark.

Who is the CEO of Zalemark Holding Company?

The CEO of Zalemark Holding Company is Xia Wu.

Who is the founder and chair of Lupos Biotechnology?

The founder and chair of Lupos Biotechnology is Dr. Nan Li.

What does this agreement reflect about Zalemark Holding Company's vision for cannabis products?

This agreement reflects Zalemark's desire to collaborate with companies that share the same vision for the future of cannabis products.